OpenAI has introduced the Rosalind Academic Plan to give eligible academic laboratories at U.S. universities sponsored access to GPT‑Rosalind, a life‑sciences model, together with the Rosalind workbench for specialized tool orchestration in areas such as medicinal chemistry, genomics and wet‑lab assistance. Under the plan, eligible labs may receive up to 30 Business Standard seats at $0 per user per month for up to 12 months; access to GPT‑Rosalind itself requires trusted‑access approval.
Purpose and significance
OpenAI frames the program as a way to support foundational academic research that can lead to long‑term advances in diagnostics, therapeutics and food systems. By lowering the cost and administrative friction for some university labs, the company intends to help researchers combine domain expertise with AI models tailored to life‑sciences workflows.
What the plan includes
- Up to 30 Business Standard seats per lab at $0 per user per month for up to 12 months.
- Access to all commercially available frontier OpenAI models within the plan’s usage limits.
- Access to GPT‑Rosalind following trusted‑access approval.
- API access is not included in this offer.
- Research data shared under the Rosalind Academic Plan is not used to train OpenAI models by default.
Eligibility and application routes
The Rosalind Academic Plan is currently available to academic labs at U.S. universities. Two main application paths are described:
- For principal investigators (PIs) and lab leads at eligible institutions that do not have an existing OpenAI Enterprise agreement: apply through the Rosalind Academic Plan trusted‑access process.
- For labs at institutions with an existing OpenAI Enterprise agreement: request access via the institution’s Enterprise account.
Once approved, a verified PI or lab lead can activate free access for up to 30 named members. Verified leads control member permissions and are responsible for ensuring approved use within their lab.
Intended research use cases
OpenAI lists several life‑science applications that GPT‑Rosalind is intended to support, including:
- Designing candidate drugs, therapeutic proteins, peptides and enzymes, and optimizing molecular interactions, selectivity, stability and developability.
- Identifying molecular disease signatures and developing liquid biopsies and other minimally invasive diagnostics for earlier detection, monitoring and treatment assessment.
- Designing and evaluating antibodies and vaccines against emerging viral variants, studying host–pathogen interactions and protective immune response durability.
- Developing approaches to correct genetic defects, modulate gene expression, design RNA therapeutics and investigate targeted delivery to tissues.
- Investigating crop resilience, plant disease and animal health, and applying genetic, nutritional and biological insights to improve food production and veterinary care.
- Studying biodiversity, adaptation, species interactions and environmental exposures to inform conservation, bioremediation and climate response.
- Exploring microbial resistance to antibiotics, antivirals and antifungals and developing new treatments for resistant infections, biofilms and persistent disease.
Verification, safeguards and ongoing oversight
OpenAI describes a verification and review process before granting GPT‑Rosalind access. Steps include:
- Verifying the institution’s legitimacy and the PI or lab lead’s identity.
- Reviewing the lead’s professional background, institutional appointment and authority to oversee lab access.
- Assessing the lab’s institutional affiliation, research activities and intended use.
- Establishing responsibilities for the lab lead and a designated institutional safety contact.
After activation, monitoring and enforcement continue. For registered high‑sensitivity use cases, safety checks consider the approved research context; OpenAI may follow up with researchers to clarify work and confirm authorization when questions arise. The stated aim is to detect potential misuse while minimizing unnecessary interruptions to authorized research.
What this means for researchers
The Rosalind Academic Plan is part of OpenAI’s broader effort to place domain‑specific AI tools in the hands of more scientists by lowering access costs. OpenAI emphasizes that many modern advances in medicine and biotechnology began with long‑term academic research, and that enabling more labs to use specialized model reasoning could accelerate discoveries with impacts beyond the laboratory.
Prospective applicants and interested lab leads at U.S. universities are directed to OpenAI’s help center for details on eligibility, application requirements and getting started.
(This article restates the contents of OpenAI’s announcement and does not add information beyond the published release.)
